| $350M | ||
| $217M | ||
| $172M | ||
| $109M | ||
| $107M | ||
| $104M |
Buys | $0 | 0 | 0 |
Sells | $59,312 | 4 | 100 |
| Kasraian Kasra | Chief Technical Officer | 0 | $0 | 1 | $1,739 | $-1,739 |
| STRECK PAUL | EVP, Head of R&D | 0 | $0 | 1 | $11,709 | $-11,709 |
| Donnelly Noel | Chief Financial Officer | 0 | $0 | 1 | $12,988 | $-12,988 |
| McArthur James G | President and CEO | 0 | $0 | 1 | $32,876 | $-32,876 |
PepGen Inc., a clinical-stage biotechnology company, develops oligonucleotide therapeutics for the treatment of severe neuromuscular and neurologic diseases in the United States. The company engages in the development of PGN-EDODM1, an EDO peptide-conjugated PMO, which is in Phase 2 clinical trial for the treatment of myotonic dystrophy type 1; and FREEDOM2-DM1, which is in Phase 2 for the treatment of myotonic dystrophy type 1. It is also involved in FREEDOM-OLE, an open label expansion study. The company was founded in 2018 and is based in …
Over the last 12 months, insiders at PepGen Inc. have bought $0 and sold $59,312 worth of PepGen Inc. stock.
On average, over the past 5 years, insiders at PepGen Inc. have bought $24.68M and sold $430,001 worth of stock each year.
There was no buying activity among insiders over the last 12 months.
The last purchase of 200,000 shares for transaction amount of $640,000 was made by Oxford Science Enterprises plc (Former 10% Owner) on 2025‑09‑30.
| 2026-05-21 | Sale | Kasraian Kasra | Chief Technical Officer | 1,233 0.0016% | $1.41 | $1,739 | +55.19% | |
| 2026-03-04 | Sale | McArthur James G | President and CEO | 5,275 0.0071% | $6.23 | $32,876 | -66.27% | |
| 2026-03-04 | Sale | Donnelly Noel | Chief Financial Officer | 2,084 0.0028% | $6.23 | $12,988 | -66.27% | |
| 2026-03-04 | Sale | STRECK PAUL | EVP, Head of R&D | 1,879 0.0025% | $6.23 | $11,709 | -66.27% | |
| 2025-09-30 | Oxford Science Enterprises plc | Former 10% Owner | 200,000 0.4223% | $3.20 | $640,000 | -30.30% | ||
| 2025-09-26 | RA CAPITAL MANAGEMENT, L.P. | 9.38M 18.0403% | $3.20 | $30M | -16.77% | |||
| 2025-05-30 | STRECK PAUL | EVP, Head of R&D | 8,375 0.0218% | $1.24 | $10,393 | +192.81% | ||
| 2025-04-17 | McArthur James G | President and CEO | 10,000 0.0377% | $1.35 | $13,550 | +221.43% | ||
| 2025-04-08 | McArthur James G | President and CEO | 41,500 0.1327% | $1.15 | $47,725 | +327.50% | ||
| 2025-02-26 | Sale | Donnelly Noel | Chief Financial Officer | 1,527 0.005% | $1.68 | $2,565 | +26.80% | |
| 2025-02-26 | Sale | DeLena Mary Beth | General Counsel | 1,432 0.0047% | $1.68 | $2,406 | +26.80% | |
| 2024-07-25 | Sale | Mellion Michelle L | Chief Medical Officer | 7,571 0.0234% | $18.06 | $136,741 | -86.54% | |
| 2024-07-24 | Sale | Mellion Michelle L | Chief Medical Officer | 201 0.0006% | $18.01 | $3,619 | -86.05% | |
| 2024-07-18 | Sale | Mellion Michelle L | Chief Medical Officer | 12,625 0.0427% | $18.20 | $229,804 | -83.87% | |
| 2024-07-16 | Sale | Mellion Michelle L | Chief Medical Officer | 5,901 0.0194% | $18.00 | $106,247 | -84.42% | |
| 2024-07-12 | Sale | Mellion Michelle L | Chief Medical Officer | 3,288 0.0108% | $18.04 | $59,331 | -81.29% | |
| 2024-07-02 | Sale | Mellion Michelle L | Chief Medical Officer | 37 0.0001% | $18.07 | $669 | -76.65% | |
| 2024-07-01 | Sale | Mellion Michelle L | Chief Medical Officer | 875 0.0029% | $18.01 | $15,760 | -78.62% | |
| 2024-06-24 | Sale | Mellion Michelle L | Chief Medical Officer | 9,260 0.0291% | $18.19 | $168,427 | -77.16% | |
| 2024-06-12 | Sale | Mellion Michelle L | Chief Medical Officer | 1,086 0.0034% | $18.06 | $19,615 | -75.13% |
| McArthur James G | President and CEO | 296326 0.4284% | $728,961.96 | 3 | 6 | +115.1% |
| STRECK PAUL | EVP, Head of R&D | 76226 0.1102% | $187,515.96 | 1 | 1 | |
| RA CAPITAL MANAGEMENT, L.P. | 18554273 26.8245% | $45.64M | 2 | 0 | <0.0001% | |
| Oxford Science Enterprises plc | Former 10% Owner | 4955388 7.1642% | $12.19M | 2 | 0 | <0.0001% |
| Shah Rajeev M. | 1302600 1.8832% | $3.2M | 1 | 0 | +7.35% | |
| Deerfield Private Design Fund V, L.P. | 476813 0.6893% | $1.17M | 1 | 0 | +7.35% | |
| KEATING LAURIE | director | 4166 0.006% | $10,248.36 | 1 | 0 | <0.0001% |
$6,788,859 | 35 | 26.72% | $151.54M | |
$7,147,964 | 34 | 24.77% | $166.39M | |
$38,621,826 | 31 | 1.43% | $157.74M | |
$74,231,875 | 30 | 40.62% | $183.78M | |
$41,526,694 | 30 | 23.89% | $135.61M |
| Increased Positions | 58 | +80.56% | 10M | +17.27% |
| Decreased Positions | 29 | -40.28% | 9M | -16.01% |
| New Positions | 31 | New | 4M | New |
| Sold Out Positions | 12 | Sold Out | 6M | Sold Out |
| Total Postitions | 101 | +40.28% | 57M | +1.26% |
| Ra Capital Management, L.P. | $143,863.00 | 29.08% | 20.06M | +9M | +87.7% | 2025-09-30 |
| Viking Global Investors Lp | $24,969.00 | 5.05% | 3.48M | +2M | +134.91% | 2025-09-30 |
| Commodore Capital Lp | $16,902.00 | 3.42% | 2.36M | +2M | New | 2025-09-30 |
| Vivo Capital, Llc | $16,670.00 | 3.37% | 2.33M | +2M | New | 2025-09-30 |
| Point72 Asset Management, L.P. | $14,555.00 | 2.94% | 2.03M | -729,171 | -26.43% | 2025-09-30 |
| Bvf Inc/Il | $13,731.00 | 2.78% | 1.92M | +2M | New | 2025-09-30 |
| Laurion Capital Management Lp | $13,567.00 | 2.74% | 1.89M | +1M | +133.38% | 2025-09-30 |
| Vanguard Group Inc | $12,679.00 | 2.56% | 1.77M | +831,333 | +88.72% | 2025-09-30 |
| Rtw Investments, Lp | $10,755.00 | 2.17% | 1.5M | +2M | New | 2025-09-30 |
| Janus Henderson Group Plc | $10,755.00 | 2.17% | 1.5M | +2M | New | 2025-09-30 |